check_circleStudy Completed

Multiple Sclerosis, Relapsing-Remitting

Real-World Betaseron Health Economic Outcomes Study for relapsing forms of multiple sclerosis

Trial purpose

A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.

Key Participants Requirements

Sex

Both

Age

18 - 65 Years

Trial summary

Enrollment Goal
226
Trial Dates
July 2007 - September 2009
Phase
N/A
Could I Receive a placebo
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States
Completed
Many Locations, United States

Primary Outcome

  • Key Objective: To collect patient reported outcomes and clinical assessments via the same web-based data capture tool in a real world setting in relapse-remitting multiple sclerosis patients
    date_rangeTime Frame:
    Baseline, 1 to12 month outcome questionnaires
    enhanced_encryption
    Safety Issue:
    No

Trial design

Real-World Betaseron® Outcomes Study (ROBUST): A twelve-month, US prospective, observational, open-label, single-arm, multi-center outcomes study of Interferon β-1b (Betaseron®) given every other day for relapsing forms of multiple sclerosis
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A